Total Payments
$7,230
2022 Payments
$647.68
Companies
42
Transactions
113
Medicare Patients
8,460
Medicare Billing
$3.6M
Payment Breakdown by Category
Consulting$3,573 (49.4%)
Food & Beverage$2,259 (31.2%)
Travel$1,379 (19.1%)
Education$19.66 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,573 | 3 | 49.4% |
| Food and Beverage | $2,259 | 101 | 31.2% |
| Travel and Lodging | $1,379 | 7 | 19.1% |
| Education | $19.66 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cardinal Health 414, LLC | $2,519 | 7 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $2,331 | 8 | $0 (2022) |
| Incyte Corporation | $376.15 | 3 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $196.91 | 11 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $182.35 | 7 | $0 (2021) |
| Octapharma USA, Inc. | $146.46 | 1 | $0 (2021) |
| Sirtex Medical Inc | $143.04 | 1 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $96.27 | 6 | $0 (2022) |
| Janssen Biotech, Inc. | $87.83 | 3 | $0 (2022) |
| GENZYME CORPORATION | $85.95 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $647.68 | 36 | Novartis Pharmaceuticals Corporation ($183.40) |
| 2021 | $1,022 | 56 | Octapharma USA, Inc. ($146.46) |
| 2020 | $16.63 | 1 | Taiho Oncology, Inc. ($16.63) |
| 2019 | $362.69 | 4 | Sirtex Medical Inc ($143.04) |
| 2018 | $335.00 | 1 | Incyte Corporation ($335.00) |
| 2017 | $4,847 | 15 | Cardinal Health 414, LLC ($2,519) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/28/2022 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.47 | General |
| 07/27/2022 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Oncology | ||||||
| 07/14/2022 | Taiho Oncology, Inc. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: Oncology | ||||||
| 07/13/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: ONCOLOGY | ||||||
| 07/07/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $20.67 | General |
| Category: Oncology | ||||||
| 06/30/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.93 | General |
| Category: Oncology | ||||||
| 06/23/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, MEKINIST | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Oncology | ||||||
| 06/21/2022 | Organon LLC | ONTRUZANT (Drug) | Food and Beverage | In-kind items and services | $5.14 | General |
| Category: TRASTUZUMAB | ||||||
| 06/16/2022 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Oncology | ||||||
| 06/16/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2022 | Myovant Sciences Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: HORMONE THERAPY | ||||||
| 06/01/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Oncology | ||||||
| 05/31/2022 | Janssen Biotech, Inc. | DARZALEX (Biological), ERLEADA | Food and Beverage | In-kind items and services | $47.90 | General |
| Category: Oncology | ||||||
| 05/27/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Oncology | ||||||
| 05/24/2022 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: HEMATOLOGY | ||||||
| 05/20/2022 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/17/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Rare Disease | ||||||
| 05/05/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.40 | General |
| Category: Hematology | ||||||
| 04/05/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.36 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 2,876 | 112,591 | $4.0M | $1.3M |
| 2022 | 49 | 2,379 | 105,339 | $3.2M | $1.2M |
| 2021 | 57 | 2,726 | 81,212 | $2.6M | $994,069 |
| 2020 | 10 | 479 | 805 | $211,187 | $56,303 |
Total Patients
8,460
Total Services
299,947
Medicare Billing
$3.6M
Procedure Codes
165
All Medicare Procedures & Services
165 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 13,800 | $1.5M | $520,947 | 35.6% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 17 | 4,780 | $434,020 | $170,649 | 39.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 244 | 950 | $340,488 | $125,668 | 36.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 52 | 5,940 | $268,080 | $110,075 | 41.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 443 | 851 | $217,181 | $78,391 | 36.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 120 | 520 | $133,330 | $49,679 | 37.3% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 52 | 6,570 | $145,830 | $39,211 | 26.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 22 | 24,000 | $72,000 | $20,888 | 29.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 158 | 405 | $54,030 | $18,829 | 34.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 19 | 141 | $146,229 | $18,726 | 12.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 243 | 288 | $51,942 | $17,955 | 34.6% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 48 | 62 | $43,245 | $16,171 | 37.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 95 | 662 | $37,664 | $14,419 | 38.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 85 | 138 | $32,523 | $12,678 | 39.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 56 | 56 | $24,780 | $8,979 | 36.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 33 | 179 | $22,543 | $8,691 | 38.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $23,122 | $8,241 | 35.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 151 | $21,563 | $8,150 | 37.8% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 11 | 810 | $139,360 | $6,711 | 4.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 26 | 16,830 | $46,410 | $6,652 | 14.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 48 | $17,376 | $6,509 | 37.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 170 | 498 | $20,832 | $5,255 | 25.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 71 | 349 | $12,702 | $4,100 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 62 | $9,664 | $3,776 | 39.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 34 | 244 | $9,832 | $3,766 | 38.3% |
About Long Dang, MD, PHD
Long Dang, MD, PHD is a Hematology healthcare provider based in Merritt Island, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528144581.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Long Dang, MD, PHD has received a total of $7,230 in payments from pharmaceutical and medical device companies, with $647.68 received in 2022. These payments were reported across 113 transactions from 42 companies. The most common payment nature is "Consulting Fee" ($3,573).
As a Medicare-enrolled provider, Dang has provided services to 8,460 Medicare beneficiaries, totaling 299,947 services with total Medicare billing of $3.6M. Data is available for 4 years (2020–2023), covering 165 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Merritt Island, FL
- Active Since 10/31/2006
- Last Updated 06/26/2025
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1528144581
Products in Payments
- OPDIVO (Biological) $2,331
- KEYTRUDA (Biological) $182.35
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $146.46
- SIR-Spheres Microspheres (Device) $143.04
- DARZALEX (Biological) $87.83
- NINLARO (Drug) $78.46
- JEVTANA (Drug) $66.25
- Nubeqa (Drug) $56.89
- XTANDI (Drug) $54.53
- LIBTAYO (Biological) $53.43
- COSELA (Drug) $53.27
- REBLOZYL (Biological) $53.18
- MEKINIST (Drug) $52.75
- BLENREP (Biological) $47.59
- TAGRISSO (Drug) $45.50
- ELIGARD (Drug) $42.08
- Enhertu (Drug) $40.25
- TASIGNA (Drug) $40.02
- KISQALI (Drug) $37.70
- PROMACTA (Drug) $37.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.